Everest MED (01952) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 4.23%, trading at HK$41.34, with a turnover of HK$26.11 million. The movement follows the company's announcement that it will present first-in-human clinical trial data for its self-developed mRNA personalized cancer vaccine, EVM16, at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data covers EVM16 both as a monotherapy and in combination with a PD-1 inhibitor (tislelizumab) for the treatment of advanced solid tumors. This clinical trial was jointly initiated by Peking University Cancer Hospital and Fudan University Shanghai Cancer Hospital, with the first patient dosed in March 2025. Results indicated that EVM16 demonstrated a favorable safety and tolerability profile, significant immunogenicity, and positive preliminary efficacy signals in patients with advanced solid tumors, supporting further clinical development. EVM16 is an mRNA personalized therapeutic cancer vaccine developed by Everest MED. Utilizing the EVER-NEO-1 "Miao Suan" system, it identifies highly immunogenic tumor neoantigens specific to each patient's cancer cell mutations and designs an mRNA vaccine encoding dozens of these neoantigens. The vaccine employs an LNP targeted delivery system for efficient antigen presentation in the body, activating the patient's own neoantigen-specific T-cell immunity to kill tumor cells and treat cancer.
Comments